Report on first half 2014

Lainate

July 30, 2014

1

2

Safe Harbour Statement

This presentation may include forward-looking statements that are based on our management’s beliefs

and assumptions and on information currently available to our management.

The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that

any of its plans will be achieved. Actual results may differ materially from those set forth in this

presentation due to the risks and uncertainties inherent in Cosmo’s ability to develop and expand its

business, successfully complete development of its current product candidates and current and future

collaborations for the development and commercialisation of its product candidates and reduce costs

(including staff costs), the market for drugs to treat IBD diseases, Cosmo’s anticipated future revenues,

capital expenditures and financial resources and other similar statements, may be "forward-looking" and

as such involve risks and uncertainties and risks related to the collaboration between Partners and Cosmo,

including the potential for delays in the development programs for Methylene Blue MMX®, Rifamycin SV

MMX®, and CB-03-01. No assurance can be given that the results anticipated in such forward looking

statements will occur. Actual events or results may differ materially from Cosmo’s expectations due to

factors which include, but are not limited to, increased competition, Cosmo’s ability to finance expansion

plans, the results of Cosmo’s research and development activities, the success of Cosmo’s products,

regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Cosmo assumes no responsibility to update forward-looking statements or to adapt them to future events

or developments.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as

of the date hereof, and Cosmo undertakes no obligation to revise or update this presentation.

3

Agenda

• Introduction and H1 2014 highlights Alessandro Della Cha’, CEO

• H1 2014 Financial review Chris Tanner, CFO

• Pipeline update Luigi Moro, CSO

• 2014 Outlook Alessandro Della Cha’, CEO

• Questions & Answers All

4 4

• Uceris® net revenues are estimated to have exceeded $ 100 m

• Lialda® market share continued improving to 31% of 5 ASA market

• Phase III clinical trial for CB-17-01 Methylene Blue MMX® in North America and EU well underway

• Developed SIC 8000, a sub-mucosal injectable composition for the extraction of polyps in the colon

• Completed CB-03-01 phase II clinical trails in acne and recovered license from Valeant

• Sold remaining 2’991’044 SNTS shares generating a net profit of € 65.1 million

• Paid a first time dividend of € 1 per share and repurchased 4% of shares in a public share buy back

H1 2014 Highlights

5

Income Statementand Statement of Comprehensive Income

EUR/1,000 30.06.2014 30.06.2013

Revenues 41,077 26,562

Other Income 22 15

Cost of sales (10,061) (9,519)

Research and development costs (9,202) (5,791)

Selling, general and administrative costs (7,230) (4,575)

Net Operating expenses (26,471) (19,870)

Operating Result 14,606 6,692

Financial income 66,818 58,542

Financial expenses (2,047) (365)

Profit Before Taxes 79,377 64,869

Income tax expenses (2,569) (1,530)

Profit For The Period 76,808 63,339

EUR/1,000 30.06.2014 30.06.2013

Profit (loss) for the period (A) 76,808 63,339

Other comprehensive income that will be not reclassified to P/L (23) 14

Other comprehensive income that will be reclassified to P/L (63,686) (8.772)

Total other comprehensive income, net of tax (B) (63,709) (8,758)

Total comprehensive income (A)+(B) 13,099 54,581

6

Discussion of income statement H2 2014

• Overall operating revenues increased by 54.6% to € 41.1 million

• Royalties increased by 104.0% to € 14.8 million

• Lialda royalties increased 1.3% to € 5.9 million

• Uceris royalties increased more than 6 times to € 8.9 million

• MMX Manufacturing increased by 96.9% to € 16.6 million

• Lialda manufacturing revenue increased by 24.4% to € 8.9 million

• Uceris manufacturing revenue increased nearly 7 times to € 9.0million

• Contract drug manufacturing for third parties increased by 9.4% to€ 5.9 million

• Revenues from own products increased from 78.8% to 85.4% of total

• license fees and milestones declined by 30.3% to € 3.7 million

• Last year there was one $ 7 million for Uceris for first sale; this year$ 5 million for first time net sales exceeding $ 75 million

7

Discussion of income statement H2 2014

• Operating costs increased by 33.2% to € 26.5 million

• COGS increased by 5.7% to € 10.1 million

• SG&A increased by 58.0% to € 7.2 million

• R&D expenditures increased by 58.9% to € 9.2 million

• Raw material and consumables were well contained at + 5.7%

• Personnel expense increased 20.3% on the back of head count increasing by10.6% and ESOP allocation

• Advertising & marketing costs increased to € 1.5 million because of the Zacoladvertising campaign

• R&D increase driven by costs for Methylene Blue MMX trial and CB-03-01 trial aswell as internal development of SIC 8000

8

Discussion of income statement H2 2014

• EBITDA increased by 103.3% to € 19.0 million from € 9.4 million

• Financial gain of € 65.1 million on sale of 2’991’044 SNTS shares

• Gross proceeds reached $ 95.7 million or € 70.4 million, the net realized gainamounted to € 65.1 million

• Net profit increased by 21.3% to € 76.8 million

• Comprehensive Income declined by 76% to € 13.1 million

9

Consolidated Statement of Financial Position

EUR/1,000 30.06.2014 31.12.2013

Non current financial assets 83,390 15,513

Other non current assets 35,496 39,160

Cash and cash equivalents 28,713 46,338

Current financial assets 24,761 121,823

Other current assets 26,652 20,170

Total assets 199,012 243,004

Medium-to long-term interest-bearingloans and borrowings

8,795 9,762

Other non-current liabilities 3,313 3,388

Short-term interest-bearing loans andborrowings

2,021 1,986

Other current liabilities 10,481 7,713

Equity attributable to owners of the company 174,390 220,140

Non controlling interest 12 15

Total equity and liabilities 199,012 243,004

10

Discussion of Statement of Financial Position I

• € 14.3 million cash were used to pay dividends and € 46.1 million cashwas used to repurchase shares in a 4% public share buy back

• This was financed by a decrease in Cash and Cash equivalents of € 17.6million which decreased by 38% to € 28.7 m and by a reduction ininvestments in financial assets by € 29.2 million or 21.2% to € 108.2million

• Intangible assets decreased by 18.7% to € 13.4 million because ofamortization of capitalized Uceris® & Cortiment® R&D

11

Discussion of Statement of Financial Position II

• Short term loans increased slightly by 1.8% to € 2.0 million because of areclassification of non current loans

• Primarily subsidized loans

• Medium term loans and borrowings declined by 1.1% to € 8.8 million

• € 7.3 million are financial lease obligations that came along with the Cristoforo

Colombo Real estate acquisition

• Equity attributable to owners of the company decreased by €45.7 millionto €174.4 m

• 14’995’743 shares issued

• 741’099 treasury shares in books, purchased at CHF 79.64

• 87.6% of total Assets are financed by Equity

12

1H 2014 Cash Flow

Cash at the end of the period 28,713Transaction with treasury shares (46,093)

Dividends paid (14,255)

Additional investment in Cosmo R&D interests(5)

Loan repayment (net of increase) (936)

Disposal of financial assets 99,081

Investment in fixed assets (net) (559)

Investment in intangibles assets (93)

Investment in financial assets available for sales (69,192)

Change in working capital (4,532)

Accrual/payment of employee benefits, other provision and taxes (311)

Income taxes paid (1,530)

Other non cash items 2,107

Financial gain on sale of financial assets available for sale (Santarus shares) (65,089)

Depreciation and amortization 4,405

Profit before taxes 79,377

Cash at the beginning of the period 46,338

(80,000) (60,000) (40,000) (20,000) 0 20,000 40,000 60,000 80,000 100,000

13

Pipeline Update

Product and Indication Drug typePreclinic

alPhase I Phase II Phase III MA Launch Partner

Uceris/Cortiment

Mild to moderate Ulcerative Colitis

Cortico-steroid

Salix- USA & upon closing

Japan

Ferring – Rest of World

Rifamycin SV MMX®

-Travellers’ Diarrhoea

-Uncomplicated diverticulitis

Antibiotic

Upon closing licensed to

Salix in USA, Latam & Asia

Dr. Falk –Europe & Australia, (excluding

Italy) Crinos –Italy

CB-17-01

- Chromendoscopy for

colorectal

cancer prevention in surveillance patients

- Chromoendoscopy for colorectal cancer

prevention in UC patients

Diagnostic

Upon closing licensed to

Salix in USA

CB-01-12

Antibody AntiTNFα

Immunosuppressant

CB-17-04

Sub mucosal injectablecomposition

Medical device

CB-03-01 (NCE)

Acne

Steroid ester, androgen antagonist

CB-03-01 (NCE)

Alopecia

Steroid ester, androgen antagonist

•CB-06-02

•Genital Warts•Tellurium

•Licensed in fromBioMas

ItalyEastern Europe

EU

UCERIS

EU

USA

EU

CORTIMENT

PoC

PoC in USA

EU

USA

USA & EU

USA

15 15

Lialda® & Mezavant® & Mesavancol ®

• Lialda® & Mesavancol® Net Sales

• H1 2014: $ 272 m (+14.3%)

• Cosmo Income

• H1 2014: € 14.8 m (+13.8%) (€ 5.9 m royalties, € 8.9 mmanufacturing)

• General royalty cap has been reached. $ 15 million royalties stillachievable by sales of Lialda®, once approved, in Japan

15

16

Uceris® & Cortiment®

• Uceris® estimated net revenues in H1

• USD 100.1 million

• Cosmo Revenue on Uceris®:

• Milestone: € 3.7 million

• Manufacturing revenue: € 7.7 million

• Royalties: € 8.9 million (based on estimated net Uceris® revenues of Salix of USD 100.1 million)

• Business Development

• If transaction with Salix closes, Salix is to license Uceris in Japan and Cosmo gets 50% of milestones and royalties

• Ferring is preparing launches of Cortiment® in 17 primarily EU countries in 2015 and 12 further EU countries in 2016

16

17 17

Rifamycin SV MMX®

• Development status• Travellers Diarrhoea:

• Trial started in Latin America: Mexico, Guatemala, Ecuador, Peru, all in all anadditional 200 patients need to be recruited to get to the target trial size of 1000

• Diverticulitis:

• Dr. Falk is conducting a phase II trial for the treatment of non complicateddiverticulitis. 61 out of a targeted 450 patients have been recruited

• Timing• TD trial expected to be completed in H1 2015

• Diverticulitis phase II scheduled to be completed in H2 2015

• Business Development:

• If Salix transaction closes then Salix get rights to entire world except for EU(which is licensed to Dr. Falk)

• 50% of milestones and royalties generated by Salix outside of US are due toCosmo

17

18

CB-17-01 Methylene Blue MMX for colon cancer diagnosis

• Development status• All in all 1230 patients to be treated in phase III in 13 sites

• Phase III trial for IBD patients in preparation

• Timing• Target for phase III trial completion is end 2014

• Business Development• If Salix transaction closes then Salix get rights to the USA

• Licensing to the RoW will commence once phase III data is in in H1 2015

19

CB-17-04 SIC 8000

• Development status• USA

• Pre submission meeting with FDA took place June 23

• Classified as a type II b medical device

• No need of clinical trials

• EU

• Pre submission meeting took place with ISS acting for EU July 28; no need for clinical trials

• Timing• Targeted for launch in EU and USA in H1 2015

• Business Development• Licensing process will commence in Q4 2014

• Salix has first right of refusal in USA

20

CB-03-01:anti adrogen for topical applications

• Development status• Acne

• EOPII meeting with FDA scheduled for September

• Possible start of phase III in Q4 14

• Alopecia

• IND requested for POC with 3 arms, 120 patients against minoxidiland placebo

• Timing• Acne: Phase III to target to be completed H2 2016

• Alopecia: POC targeted to be competed end 2015

• Business Development• Regained product from Valeant

• Valeant has first right of refusal if we decide to re-license

• Spin off initiatives will start in H2 2014

21

Outlook for 2014

Operations

• Strong continued growth in Uceris expected

• Cap in Lialda attained. Slight continued growth in manufacturing revenues

• Normal development in general contract drug manufacturing

Clinical development

• Restart of Phase III TD Rifamycin SV MMX in Latin America

• EOPII meeting with FDA for CB-03-01 acne; first patient Q1 2015

• Continuation of POC alopecia trial

• Completion of phase III Methylene Blue MMX in North America and EU

• Continuation of genital warts trial

Business development

• Closing of Salix transaction

• Start licensing process for SIC 8000

22

Cosmo Pharmaceuticals

Information Contacts

• Half-Year Report 2014: 30 July 2014

• Number of shares: 14,995,743

• Listing: SIX Swiss exchange, Main board

• ISIN: IT0004167463

• Alessandro Della Cha’, CEOadellacha@cosmopharma.com

• Chris Tanner, CFOctanner@cosmopharma.comph: +39-02-9333’7276

• Giuseppe Cipriano, COOgcipriano@cosmopharma.com

• Luigi Moro, CSOlmoro@cosmopharma.com